Although serum S100B may be elevated in acute neuronal damage, S100B levels were decreased in patients with underlying neurodegenerative disease (Chaves et al., 2010) and also observed in patients who carry lower pain thresholds diagnosed with fibromyalgia (Zanette et al., 2014). Here, S100B is linked to neurodegenerative disease.